KODIAK SCIENCES INC. FORWARD-LOOKING STATEMENTS This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: the ability of our ABC® duets to tackle glaucoma and geographic atrophy; a possible first biologics license application (BLA) filing in multiple large indications; expected benefits from the enhanced formulations of tarcocimab and KSI-501; expanding our late-phase portfolio and the commercial opportunity for KSI-101; the ability of LIDAR-based imaging technologies to enable smaller, more targeted retina clinical trials in the future; the expected timing of topline data readouts; and our upcoming Investor R&D update. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “will,” “could,” “plan,” “believe,” and other similar expressions among others. Forward-looking statements are based on our current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially and adversely from those in or implied by such forward-looking statements. For a discussion of risks and uncertainties and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. These forward- looking statements speak only as of the date hereof and Kodiak undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.